SG11202104657RA - Formulation of contrast media and process of preparation thereof - Google Patents

Formulation of contrast media and process of preparation thereof

Info

Publication number
SG11202104657RA
SG11202104657RA SG11202104657RA SG11202104657RA SG11202104657RA SG 11202104657R A SG11202104657R A SG 11202104657RA SG 11202104657R A SG11202104657R A SG 11202104657RA SG 11202104657R A SG11202104657R A SG 11202104657RA SG 11202104657R A SG11202104657R A SG 11202104657RA
Authority
SG
Singapore
Prior art keywords
formulation
preparation
contrast media
contrast
media
Prior art date
Application number
SG11202104657RA
Inventor
Stephan Holzschuh
Thomas Frenzel
Gregor Jost
Jessica Lohrke
Wolfgang Ebert
Thomas Brumby
Wolfgang Halfbrodt
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of SG11202104657RA publication Critical patent/SG11202104657RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
SG11202104657RA 2018-11-23 2019-11-21 Formulation of contrast media and process of preparation thereof SG11202104657RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18208090 2018-11-23
PCT/EP2019/082117 WO2020104602A1 (en) 2018-11-23 2019-11-21 Formulation of contrast media and process of preparation thereof

Publications (1)

Publication Number Publication Date
SG11202104657RA true SG11202104657RA (en) 2021-06-29

Family

ID=64456867

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104657RA SG11202104657RA (en) 2018-11-23 2019-11-21 Formulation of contrast media and process of preparation thereof

Country Status (16)

Country Link
US (1) US11944690B2 (en)
EP (1) EP3883613A1 (en)
JP (1) JP2022508185A (en)
KR (1) KR20210095168A (en)
CN (1) CN113164628A (en)
AU (1) AU2019382881A1 (en)
BR (1) BR112021007707A2 (en)
CA (1) CA3120665A1 (en)
CL (1) CL2021001331A1 (en)
CO (1) CO2021006034A2 (en)
IL (1) IL283281A (en)
JO (1) JOP20210114A1 (en)
MX (1) MX2021006024A (en)
PE (1) PE20211471A1 (en)
SG (1) SG11202104657RA (en)
WO (1) WO2020104602A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4335461A1 (en) * 2022-09-09 2024-03-13 Bayer AG Combinations of contrast agents

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4485237A (en) 1983-03-08 1984-11-27 The United States Of America As Represented By The Secretary Of The Navy Insensitive polynitramine compound
DE3625417C2 (en) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecane derivatives
US5039512A (en) 1986-08-04 1991-08-13 Salutar, Inc. NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes
DE3640708C2 (en) * 1986-11-28 1995-05-18 Schering Ag Improved pharmaceuticals containing metals
DE3728525A1 (en) 1987-08-24 1989-03-16 Schering Ag MULTI-CORE SUBSTITUTED COMPLEX ILLUMINATORS, COMPLEX AND COMPLEX SALTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
DE4001655A1 (en) 1990-01-18 1991-07-25 Schering Ag 6-RING MACROCYCLIC TETRAAZA COMPOUNDS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL PRODUCTS CONTAINING THEM
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5138923A (en) 1988-11-18 1992-08-18 Atlas Die, Inc. Rotary die cutter
US5011925A (en) 1989-03-09 1991-04-30 Mallinckrodt, Inc. Morpholinoamido EDTA derivatives
JPH05503072A (en) 1989-08-28 1993-05-27 ザ・ゼネラル・ホスピタル・コーポレーション Hydroxy-aryl metal chelates for diagnostic NMR imaging
WO1991005762A1 (en) 1989-10-23 1991-05-02 Cockbain, Julian, Roderick, Michaelson Multi-site metal chelating agents
GB9320277D0 (en) 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
CA2039399C (en) 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
US5167942A (en) 1990-11-21 1992-12-01 Board Of Regents, The University Of Texas System Methods for the preparation of molecular sieves, including zeolites, using metal chelate complexes
US5141740A (en) 1990-11-21 1992-08-25 Mallinckrodt Medical, Inc. Complexes and compositions for magnetic resonance imaging and usage methods
WO1992009884A1 (en) 1990-11-21 1992-06-11 Mallinckrodt Medical, Inc. Alkoxyamide derivatized chelates for mri
JPH06507174A (en) 1991-04-22 1994-08-11 マリンクロッド・メディカル・インコーポレイテッド Methods for detecting and localizing tissues with neurokinin 1 receptors
WO1992021017A1 (en) 1991-05-23 1992-11-26 Unger Evan C Liposoluble compounds for magnetic resonance imaging
US6875864B2 (en) 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
AU3221993A (en) 1991-11-27 1993-06-28 Phanos Technologies, Inc. Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
SG48889A1 (en) 1991-12-10 1998-05-18 Dow Chemical Co Bicycle-polyamacrocyclocarboxylic acid complexes conjugates preparation and use as contrast agents
US5324503A (en) 1992-02-06 1994-06-28 Mallinckrodt Medical, Inc. Iodo-phenylated chelates for x-ray contrast
DE4232925A1 (en) 1992-09-28 1994-03-31 Diagnostikforschung Inst 3-, 8-substituted deuteroporphyrin derivatives, pharmaceutical compositions containing them and process for their preparation
EP0703790B1 (en) 1993-06-02 2000-08-16 BRACCO S.p.A. Iodinated paramagnetic chelates, and their use as contrast agents
IT1264690B1 (en) 1993-07-08 1996-10-04 Bracco Spa IODURATED OLIGOMER COMPOSITES AND DIAGNOSTIC COMPOSITIONS CONTAINING THE SAME
AU1694895A (en) 1994-01-28 1995-08-15 Mallinckrodt Medical, Inc. Functionalized aza-bimacrocyclic ligands for imaging applications
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
DE4425857A1 (en) 1994-07-07 1996-01-11 Schering Ag Cascade polymer complexes, processes for their preparation and pharmaceutical compositions containing them
ZA958789B (en) 1994-10-21 1996-05-29 Nihon Mediphysics Co Ltd Diagnostic imaging agent
US5672335A (en) 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
US5707605A (en) 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
DE19525924A1 (en) 1995-07-04 1997-01-09 Schering Ag Cascade polymer complexes, processes for their preparation and pharmaceutical compositions containing them
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
DE19549286A1 (en) 1995-12-22 1997-06-26 Schering Ag Cascade polymer complexes, processes for their preparation and pharmaceutical compositions containing them
DE19603033A1 (en) 1996-01-19 1997-07-24 Schering Ag Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics
DE19608278A1 (en) 1996-02-23 1997-08-28 Schering Ag Pharmaceutical compositions containing perfluoroalkyl-containing metal complexes, and their use in tumor therapy and interventional radiology
IT1283218B1 (en) 1996-03-08 1998-04-16 Bracco Spa POLYKELANTS, THEIR COMPLEXES WITH METALLIC IONS, THEIR PREPARATION AND THEIR USES
US5866562A (en) 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
DE19652386A1 (en) 1996-12-04 1998-06-10 Schering Ag Process for the preparation of metal complex carboxamides
US6045776A (en) 1996-12-04 2000-04-04 Schering Aktiengesellschaft Process for the production of metal-complex carboxylic acid amides
US5919433A (en) 1996-12-04 1999-07-06 Schering Aktiengesellschaft Macrocyclic metal complex carboxylic acids, their use as well as process for their production
DE19652387A1 (en) 1996-12-04 1998-06-10 Schering Ag Macrocyclic metal complex carboxylic acids, their use and processes for their preparation
DE19729013A1 (en) 1997-07-03 1999-02-04 Schering Ag Oligomeric, perfluoroalkyl-containing compounds, processes for their preparation and their use in NMR diagnostics
US6019959A (en) 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
DE19744003B4 (en) 1997-09-26 2004-07-08 Schering Ag Contrast agent for infarct and necrosis imaging
DE69811931T2 (en) 1997-10-27 2003-12-18 Res Corp Technologies Inc MRI AGENTS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
DE19831217A1 (en) 1998-07-03 2000-01-05 Schering Ag New porphyrin derivatives, pharmaceutical compositions containing them and their use in photodynamic therapy and MRI diagnostics
EP0998946A1 (en) 1998-08-14 2000-05-10 K.U. Leuven Research & Development Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
FR2794744B1 (en) 1999-06-09 2001-09-21 Guerbet Sa METAL COMPLEXES OF BICYCLIC POLYAMINOACIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN MEDICAL IMAGING
US6221476B1 (en) 1999-06-11 2001-04-24 Ibc Advanced Technologies, Inc. Polymeric membranes functionalized with polyhydroxypyridinone ligands
US6232265B1 (en) 1999-06-11 2001-05-15 Ibc Advanced Technologies, Inc. Particulate solid supports functionalized with polyhydroxypyridinone ligands
DE19930177B4 (en) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolecular associating compounds and their use
DE19948651B4 (en) 1999-09-29 2006-10-05 Schering Ag Galenic formulations containing para and diamagnetic perfluorinated compounds, their preparation and use
EP1088559A3 (en) 1999-09-29 2002-10-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Galenic formulations
DE10002939C1 (en) 2000-01-13 2001-09-20 Schering Ag New aromatic-substituted tetraazacyclododecane-triacetic acid paramagnetic metal complex compounds, are useful as contrast agents for magnetic resonance imaging of necrotic or infarction tissue
EP1251876A2 (en) 2000-01-22 2002-10-30 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
US20020052354A1 (en) 2000-01-27 2002-05-02 Schering Ag Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
IT1317862B1 (en) 2000-02-29 2003-07-15 Bracco Spa CONJUGATES OF BILIARY ACIDS WITH COMPLEX CHELATES OF METAL IONS AND THEIR USE.
CN1582166A (en) 2000-06-21 2005-02-16 布里期托尔－迈尔斯斯奎布药品公司 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001097860A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
DE10040381C1 (en) 2000-08-11 2002-06-06 Schering Ag Perfluoroalkyl-containing complexes with sugar residues, process for their preparation and their use
DE10066210B4 (en) 2000-08-11 2008-02-28 Bayer Schering Pharma Ag Use of perfluoroalkyl-containing metal complexes as contrast agents in MR imaging for plaque imaging
DE10040858C2 (en) 2000-08-11 2003-12-18 Schering Ag Perfluoroalkyl-containing complexes with polar residues, process for their preparation and their use
IL145723A0 (en) 2000-10-11 2002-07-25 Nihon Mediphysics Co Ltd Process for producing an amide compound
US20030050452A1 (en) 2000-12-26 2003-03-13 Yuji Hashiguchi Process for producing metal complex of aminooligosaccharide derivative
US20030004236A1 (en) 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
DE10135355C1 (en) 2001-07-20 2003-04-17 Schering Ag Conjugates of macrocyclic metal complexes with biomolecules and their use in the preparation of NMR and radiodiagnostic agents and radiotherapy
DE10135356C1 (en) 2001-07-20 2003-04-17 Schering Ag Macrocyclic metal complexes and their use for the preparation of conjugates with biomolecules
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
ITMI20011708A1 (en) 2001-08-03 2003-02-03 Bracco Imaging Spa CONJUGATES OF PEPTIDES, THEIR DERIVATIVES WITH METALLIC COMPLEXES AND USE FOR DIAGNOSTIC INVESTIGATION THROUGH IMAGING FOR MAGNETIC RESONANCE (M
FR2836916B1 (en) 2002-03-05 2004-06-11 Guerbet Sa GADOLINIUM CHELATE OLIGOMERS, THEIR APPLICATION AS CONTRAST PRODUCTS IN MAGNETIC RESONANCE IMAGING AND THEIR SYNTHESIS INTERMEDIARIES
US20030198597A1 (en) 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
DE10231799B4 (en) 2002-07-10 2006-10-05 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast agents in MR imaging for the presentation of intravascular thrombi
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
DE10307759B3 (en) 2003-02-19 2004-11-18 Schering Ag Trimers of macrocyclically substituted benzene derivatives, their production and use as contrast media and pharmaceutical compositions containing them
WO2005001415A2 (en) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
AR047692A1 (en) 2003-07-10 2006-02-08 Epix Medical Inc IMAGES OF STATIONARY WHITE
DE102004023093B3 (en) 2004-05-05 2006-03-02 Schering Ag Trimere macrocyclic substituted halogen-benzene derivatives
DE102004026103A1 (en) 2004-05-25 2005-12-22 Schering Ag Trimere macrocyclic substituted aminoisophthalic acid-halogenated benzene derivatives
WO2006002873A2 (en) 2004-07-02 2006-01-12 Bracco Imaging Spa 1 , 4 -bis (carboxymethyl) -6- ' bis ( carboxymethyl) amino ! -6 -methyl- perhydro-1 , 4 diazepine (aazta) derivatives as ligands in high relaxivity contrast agents for use in magnetic resonance imaging (mri )
WO2006014530A2 (en) 2004-07-07 2006-02-09 The General Hospital Corporation Imaging of enzyme activity
US20060057071A1 (en) 2004-09-14 2006-03-16 Wing-Tak Wong Paramagnetic complexes with pendant crown compounds showing improved targeting-specificity as MRI contrast agents
US7205385B2 (en) 2004-11-12 2007-04-17 General Electric Company Polymerization method for the synthesis of polypeptide imaging agents
WO2006080022A2 (en) 2005-01-31 2006-08-03 Yeda Research And Development Co. Ltd. Mri contrast agents for diagnosis and prognosis of tumors
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
FR2891830B1 (en) 2005-10-07 2011-06-24 Guerbet Sa SHORT AMINOALCOHOL COMPOUNDS AND METAL COMPLEXES FOR MEDICAL IMAGING
WO2007064226A2 (en) 2005-12-01 2007-06-07 Ge Healthcare As Method of dynamic nuclear polarisation (dnp) using a trityl radical and a paramagnetic metal ion
CA2629143A1 (en) 2005-12-02 2007-06-07 Ge Healthcare As Multimeric magentic resonance contrast agents
CN101378784B (en) 2005-12-16 2013-06-12 通用电气医疗集团股份有限公司 Method to produce hyperpolarised carboxylates
US20080058636A1 (en) 2005-12-29 2008-03-06 Epix Pharmaceuticals, Inc. Methods of myocardial imaging
US20070202047A1 (en) 2006-01-05 2007-08-30 Markus Wolf Polyamine-substituted ligands for use as contrast agents
EP1815870A1 (en) 2006-02-01 2007-08-08 DKFZ Deutsches Krebsforschungszentrum Cyanine dye compounds linked to metal chelator for bi-modal diagnostic imaging
WO2007100563A2 (en) 2006-02-24 2007-09-07 Mallinckrodt Inc. Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates
WO2007112100A2 (en) 2006-03-24 2007-10-04 The University Of Utah Research Foundation Highly fluorinated oils and surfactants and methods of making and using same
CN101415446A (en) 2006-03-29 2009-04-22 通用电气医疗集团股份有限公司 Method to produce hyperpolarised carboxylates and sulphonates
US20090110640A1 (en) 2006-03-29 2009-04-30 Oskar Axelsson Contrast agents for magnetic resonance imaging and spectroscopy consisting of a cyclic oligoamid core of 3 to 4 identicial monomer units with 3 to 4 paramagnetic chelate side chains
WO2007128873A1 (en) 2006-05-05 2007-11-15 Wallac Oy A method for the preparation of maleimido derivatives of biomolecule labeling reactants and conjugates derived thereof
DE102006021495A1 (en) 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Use of metal chelate containing perfluorinated alkyl-residue, chelator-residue and metal ion equivalent to the atomic number, for the production of diagnostic agent for representation of amyloid-containing plaques
JP2008012596A (en) 2006-07-03 2008-01-24 Aji Kk Holding device
EP2076557A4 (en) 2006-08-11 2012-08-29 Starpharma Pty Ltd Polylysine dendrimer contrast agent
CA2660717A1 (en) 2006-08-17 2008-02-21 Epix Pharmaceuticals, Inc. Methods for lymph system imaging
DE102007002726A1 (en) 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft New cascade polymer complexes, processes for their preparation and pharmaceutical compositions containing them
EP1980251A1 (en) 2007-04-13 2008-10-15 Glaxo Group Limited Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
CN101970014A (en) 2007-07-26 2011-02-09 通用电气医疗集团英国有限公司 Imaging medium comprising hyperpolarised 13c-lactate and use thereof
US20110250138A1 (en) 2007-08-01 2011-10-13 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
US20110243855A1 (en) 2007-08-27 2011-10-06 Anna Gisselsson Method and imaging medium for use in the method
JP2010537657A (en) 2007-09-07 2010-12-09 ジーイー・ヘルスケア・リミテッド Method for measuring PDH activity and imaging medium for use in said method
FR2921929B1 (en) 2007-10-08 2013-01-11 Commissariat Energie Atomique PROCESS FOR THE PREPARATION OF POLYMERIC MATERIALS DOPED BY METALLIC ELEMENTS AND MATERIALS OBTAINED THEREBY
DE102007058220A1 (en) 2007-12-03 2009-06-04 Bayer Schering Pharma Aktiengesellschaft New metal complexes useful e.g. for manufacturing agent for X-ray diagnostics and magnetic resonance tomography-diagnostics of brain infarcts and liver tumor, and/or space-process in liver and abdomen tumors and musculoskeletal tumors
EP2072061A1 (en) 2007-12-19 2009-06-24 GE Healthcare Limited Composition and method for generating a metabolic profile using 13C-MR detection
ATE544474T1 (en) 2007-12-21 2012-02-15 Ge Healthcare Ltd MAGNETIC RESONANCE IMAGING MEANS, IMAGING MEDIUM AND METHOD FOR IMAGING USING SUCH IMAGING MEDIUM
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
US8545813B2 (en) 2008-01-25 2013-10-01 Northwestern University Pre-templated macromolecular architectures with multiple Gd(III) complexes and methods of use as MRI contrast agents
WO2009098191A2 (en) 2008-02-04 2009-08-13 Ge Healthcare Limited Method to produce hyperpolarised amino acids and aminosulphonic acids
WO2009098192A1 (en) 2008-02-04 2009-08-13 Ge Healthcare Limited Mr imaging agent or medium compressing hzperpolarised 13c alanine and methods of imaging wherein such an imaging medium is used
US20090208421A1 (en) * 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
EP2279190A1 (en) 2008-04-18 2011-02-02 Ge Healthcare As Compounds comprising paramagnetic chelates arranged around a central core and their use in magneto resonance imaging and spectroscopy
US20130136691A1 (en) 2008-05-19 2013-05-30 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
EP2149567A1 (en) 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Cyclic polyamines for binding phosphatidylserine
EP2341944B1 (en) 2008-09-30 2019-06-26 Curium US LLC Conjugates of hexose and metal coordinating compounds for imaging purposes
US20110217241A1 (en) 2008-11-14 2011-09-08 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
FR2939318B1 (en) 2008-12-10 2012-07-13 Guerbet Sa ENCAPSULATION SYSTEM FOR IMAGING CEST WITH QUELATE Q HIGHER OR EQUAL TO 2
HUE059796T2 (en) 2009-03-19 2022-12-28 Univ Johns Hopkins Psma-targeting compounds and uses thereof
WO2010147666A1 (en) 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
US20110081428A1 (en) 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
DE102009053171B4 (en) * 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Process for the preparation of the calcium complex of dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid (Calcobutrol)
NO331773B1 (en) 2009-12-18 2012-03-26 Ge Healthcare As Manganese chelates, compositions comprising such and their use as contrast agents for magnetic resonance imaging (MRI)
US9221759B2 (en) 2010-01-13 2015-12-29 Rutgers, The State University Of New Jersey Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
JP5758982B2 (en) 2010-04-08 2015-08-05 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． Method for producing hyperpolarized substrate and method for MRI
EP2397466B1 (en) 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
EP2457594A1 (en) 2010-11-05 2012-05-30 Bracco Imaging S.p.A Cest systems exhibiting a concentration independent responsiveness
US9011816B2 (en) 2011-03-25 2015-04-21 Case Western Reserve University Fibronectin targeting contrast agent
EP2699272A4 (en) 2011-04-20 2014-10-15 Rf Therapeutics Inc Targeted contrast agents and uses thereof
AU2012244791B2 (en) 2011-04-21 2017-04-27 Bayer Intellectual Property Gmbh Preparation of high-purity gadobutrol
CA2844151C (en) 2011-08-05 2022-11-29 John W. Babich Radiolabeled prostate specific membrane antigen inhibitors
CN102973955B (en) 2011-09-06 2016-03-23 中国科学院福建物质结构研究所 A kind of magnetic resonance imaging contrast containing trivalent aluminium
CN102442996B (en) 2011-09-16 2014-09-24 中山大学附属第一医院 Polyamine micromolecular developer, production method and application thereof
ES2414291B2 (en) 2011-12-16 2014-02-13 Universitat De Valencia MACROCYCLIC COMPOUNDS OF SCORPING TYPE AND ITS USE AS ANTIPARASITARIES.
KR101336071B1 (en) 2012-01-04 2013-12-05 한국원자력의학원 Dual MRI/CT contrast agent and a process for the preparation thereof
CN102614531B (en) 2012-04-06 2013-06-05 中国科学院长春应用化学研究所 Multi-core non-ion type magnetic resonance imaging contrast agent using diacetyl benzene or triacetyl benzene as linker
US9585975B2 (en) 2012-04-27 2017-03-07 Northwestern University MRI contrast agents
KR101456233B1 (en) 2012-08-09 2014-11-04 한국원자력의학원 Aminocyclopentane carboxylic acid-containing cyclo RGD derivatives, a process for the preparation thereof and a MRI contrast agent comprising the same
KR101456234B1 (en) 2012-08-09 2014-11-04 한국원자력의학원 Aminocyclohexane carboxylic acid-containing cyclo RGD derivatives, a process for the preparation thereof and a MRI contrast agent comprising the same
PT2900279T (en) 2012-09-25 2019-10-14 Advanced Accelerator Applications Usa Inc Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
WO2014075079A1 (en) 2012-11-12 2014-05-15 The General Hospital Corporation Peptidic structures incorporating an amino acid metal complex and applications in magnetic resonance imaging
ES2738474T3 (en) 2013-01-14 2020-01-23 Molecular Insight Pharm Inc Triazine-based radiopharmaceuticals and radioimageological agents
CN105189521A (en) 2013-02-12 2015-12-23 拜耳医药股份公司 Metal chelate compounds for binding to the platelet specific glycoprotein IIb/IIIa
BR112015026473B1 (en) 2013-04-26 2020-12-01 Guerbet liquid pharmaceutical compositions and process for preparing them and contrast medium for medical imaging
US9463254B2 (en) 2013-06-07 2016-10-11 The Board Of Regents Of The University Of Texas System Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI
CN103554185A (en) 2013-07-04 2014-02-05 上海工程技术大学 Macrocyclic polyamine polydentate ligands and synthesis method tehreof
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
EP2873679A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
CN103611171B (en) 2013-11-25 2015-03-25 中国科学院长春应用化学研究所 Non-ionic multi-nuclear magnetic resonance imaging contrast medium taking tetrabenzoylmethane as interconnect and preparation method thereof
EP3536345A1 (en) 2014-05-06 2019-09-11 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
US11324827B2 (en) 2014-10-01 2022-05-10 Xiamen Sinopeg Biotech Co., Ltd. Multifunctionalized polyethylene glycol derivative and preparation method therefor
US20180221513A1 (en) 2015-03-16 2018-08-09 Northwestern University Contrast-agent-labeled peptide amphiphile nanofibers
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US20160375155A1 (en) 2015-06-29 2016-12-29 Collagen Medical, LLC Collagen Imaging Compositions
US10927108B2 (en) 2015-08-17 2021-02-23 Southwestern Oklahoma State University Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same
JP7049993B2 (en) 2015-11-30 2022-04-07 ジーイー・ヘルスケア・アクスイェ・セルスカプ Preparation containing concomitant use of MRI contrast agent
AU2016368542B2 (en) 2015-12-10 2020-07-16 Bracco Imaging Spa Contrast agents
SG11201804412SA (en) 2015-12-10 2018-06-28 Bracco Imaging Spa Dimeric contrast agents
US10656229B2 (en) 2016-04-06 2020-05-19 Northwestern University Magnetic barcode imaging
US11007283B2 (en) 2016-04-13 2021-05-18 Bracco Imaging S.P.A. Contrast agents
JP7034160B2 (en) * 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト High relaxation gadolinium chelate compound for use in magnetic resonance imaging
KR20190091441A (en) 2016-12-12 2019-08-06 브라코 이미징 에스.피.에이. Dimer contrast agent

Also Published As

Publication number Publication date
CO2021006034A2 (en) 2021-05-20
US20220008562A1 (en) 2022-01-13
IL283281A (en) 2021-07-29
WO2020104602A1 (en) 2020-05-28
US11944690B2 (en) 2024-04-02
MX2021006024A (en) 2021-07-06
BR112021007707A2 (en) 2021-07-27
CA3120665A1 (en) 2020-05-28
EP3883613A1 (en) 2021-09-29
CL2021001331A1 (en) 2021-10-22
CN113164628A (en) 2021-07-23
KR20210095168A (en) 2021-07-30
AU2019382881A1 (en) 2021-05-20
PE20211471A1 (en) 2021-08-05
JP2022508185A (en) 2022-01-19
JOP20210114A1 (en) 2023-01-30

Similar Documents

Publication Publication Date Title
EP3437637A4 (en) Pharmaceutical preparation of palbociclib and preparation method thereof
HK1252030A1 (en) Oral formulation of glucokinase activators and preparation method thereof
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
EP3682884A4 (en) Crystal form of gsk1278863 and preparation method and pharmaceutical use thereof
EP3749343A4 (en) Formulation and method of use
EP3426227A4 (en) Composition and method of use of colchicine oral liquid
EP3380525A4 (en) Pharmaceutical formulations and methods of use thereof
HK1246656A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EP3416665A4 (en) Formulation and method of use
IL266132A (en) Pharmaceutical formulations and methods of making the same
SG11202009315WA (en) Formulation and method of preparation
EP3731833A4 (en) Compositions containing thymohydroquinone and their method of preparation
ZA202003590B (en) Process for the preparation of opicapone and intermediates thereof
IL290185A (en) Solid state forms of risdiplam and process for preparation thereof
EP3572399A4 (en) Crystal form of gft-505 and preparation method and use thereof
EP3503885A4 (en) Pharmaceutical composition and methods of uses
EP3485886A4 (en) Oral pharmaceutical composition of tecovirimat and preparation method therefor
IL283281A (en) Formulation of contrast media and process of preparation thereof
EP3880183A4 (en) Pharmaceutical preparation of fruquintinib and use thereof
EP3648777A4 (en) Exosomes and methods of use thereof
EP3576761A4 (en) Herbo-mineral formulation for the treatment of cancer and method of preparation thereof
EP3481181A4 (en) Poultry probiotic vaccine compositions and methods of use thereof
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use
EP3619193A4 (en) Amino-aryl-benzamide compounds and methods of use thereof
EP3525787A4 (en) Methods of treatment and pharmaceutical compositions using bcn057 or bcn512